Literature DB >> 21728902

A disintegrin and metalloprotease -8 and -15 and susceptibility for ascending aortic dissection.

Mari Levula1, Timo Paavonen, Timo Valo, Markku Pelto-Huikko, Reijo Laaksonen, Mika Kahonen, Ari Huovila, Terho Lehtimaki, Matti Tarkka, Ari A Mennander.   

Abstract

BACKGROUND. Dilatation of the ascending aorta (AA) is affected by extra-cellular matrix modifications and inflammation. A disintegrin and metalloproteases (ADAMs) may reveal differences between AA and ascending aortic dissection (AD). We characterized the inflammatory histology of AD and AA and examined the role of ADAM8 and -15 in these diseases. MATERIAL AND METHODS. Aortic wall histology and immunohistochemistry for leukocytes, T- and B-lymphocytes, plasma cells, macrophages, endothelial cells, smooth muscle cells, cell proliferation, elastase and Van-Gieson-staining were performed to 40 consecutive patients that underwent surgery for AA or AD. The expressions of ADAM8 and -15 mRNA and proteins were evaluated using QRT-PCR and immunohistochemistry. RESULTS. Thirty-four patients were enrolled, of which 29 had AA and five had AD of the ascending aorta. B-cells throughout the aortic wall and intimal plasma cells were more numerous during AD as compared with AA (p < 0.05). The gene expressions for ADAM8 and -15 were notably lower in AA as compared with AD. The median for down-regulation of ADAM8 and -15 in AA was -2.7 and -1.8, respectively. ADAM8 and -15 were mainly found in the media layer in patients with AD. Two of the patients with AA and increased ADAMs developed AD of the remaining aorta. CONCLUSIONS. The involvement of ADAM8 and -15 together with inflammation consisting of B-cells may indicate active remodelling of the aortic wall leading to AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21728902     DOI: 10.3109/00365513.2011.591939

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  A particular phenotype of ascending aorta aneurysms as precursor of type A aortic dissection.

Authors:  Calogera Pisano; Emiliano Maresi; Daniele Merlo; Carmela Rita Balistreri; Giuseppina Candore; Marco Caruso; Massimiliano Codispoti; Giovanni Ruvolo
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-08-14

Review 2.  Disintegrin and Metalloproteinases (ADAMs [A Disintegrin and Metalloproteinase] and ADAMTSs [ADAMs With a Thrombospondin Motif]) in Aortic Aneurysm.

Authors:  Tolga Kilic; Keisuke Okuno; Satoru Eguchi; Zamaneh Kassiri
Journal:  Hypertension       Date:  2022-05-11       Impact factor: 9.897

3.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

4.  Aiming at one-stage corrective surgery for extended thoracic aortic dilatation.

Authors:  Eetu Niinimaki; Henri Kajander; Timo Paavonen; Thanos Sioris; Ari Mennander
Journal:  Int J Angiol       Date:  2014-06

Review 5.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

6.  Ascending aortic wall degeneration in patients with bicuspid versus tricuspid aortic valve.

Authors:  Ari Mennander; Ivana Kholova; Saku Pelttari; Timo Paavonen
Journal:  J Cardiothorac Surg       Date:  2022-05-07       Impact factor: 1.522

7.  Differentially expressed genes and canonical pathways in the ascending thoracic aortic aneurysm - The Tampere Vascular Study.

Authors:  Miska Sulkava; Emma Raitoharju; Ari Mennander; Mari Levula; Ilkka Seppälä; Leo-Pekka Lyytikäinen; Otso Järvinen; Thomas Illig; Norman Klopp; Nina Mononen; Reijo Laaksonen; Mika Kähönen; Niku Oksala; Terho Lehtimäki
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

8.  Ascending aortic estrogen receptor positivity and aortic valve stenosis.

Authors:  Ari Mennander; Nitta-Nea Valtonen; Eetu Niinimäki; Ivana Kholová; Timo Paavonen
Journal:  Anatol J Cardiol       Date:  2020-11       Impact factor: 1.596

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.